# GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer

Source: https://onco.cc/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/  
OnCo record `paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The MEK inhibitor trametinib more than doubled the time to progression compared with chemotherapy or hormone therapy in recurrent low-grade serous ovarian cancer, the first positive randomised trial in this slow-growing, chemotherapy-resistant disease.

## Summary

Phase 2/3 trial of 260 patients with recurrent low-grade serous carcinoma of the ovary or peritoneum randomised to trametinib or investigator's choice of letrozole, tamoxifen, weekly paclitaxel, pegylated liposomal doxorubicin or topotecan.

Median progression-free survival was 13.0 versus 7.2 months (hazard ratio 0.48) and response 26 versus 6 percent; skin rash, anaemia and hypertension were common with trametinib.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet
- Year: 2022
- DOI: 10.1016/S0140-6736(21)02175-9
- Authors: Gershenson DM, Miller A, Brady WE, et al.
- Findings: Median progression-free survival 13.0 vs 7.2 months; hazard ratio 0.48.; Objective response 26 percent vs 6 percent.
- What it means: MEK inhibition is a standard option for recurrent low-grade serous ovarian cancer, and the trial validated the MAPK pathway as the disease's therapeutic target, now extended by avutometinib-defactinib.
- Caveats: Open-label; overall survival not significantly different with crossover.; Toxicity led to dose reductions in many patients.

## Sources

- Lancet 2022: https://doi.org/10.1016/S0140-6736(21)02175-9
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35123694/

## Connected records

- cancers: [Low-grade serous ovarian cancer](https://onco.cc/cancers/low-grade-serous-ovarian-cancer/)
- drugs: [Trametinib](https://onco.cc/drugs/trametinib/)
- journals: [The Lancet](https://onco.cc/journals/lancet/)

---
JSON: https://onco.cc/api/v1/entities/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022.json